Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4).
Volta
Mattia
M
Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara, Ferrara Italy.
Marti
Matteo
M
McDonald
John
J
Molinari
Stefano
S
Camarda
Valeria
V
Pelà
Michela
M
Trapella
Claudio
C
Morari
Michele
M
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D001562:Benzimidazoles / Q000494:pharmacology*; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D034242:Cyclooctanes / Q000494:pharmacology*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009043:Motor Activity / Q000187:drug effects; D016627:Oxidopamine / Q000633:toxicity; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011957:Receptors, Opioid / Q000187:drug effects*; D000094942:Nociceptin Receptor
C551462:1-(1-cyclooctylmethyl-5-(1-hydroxy-1-methylethyl)-1,2,3,6-tetrahydropyridin-4-yl)-3-ethyl-1,3-dihydrobenzoimidazol-2-one; D000978:Antiparkinson Agents; D001562:Benzimidazoles; D034242:Cyclooctanes; C402921:J 113397; D010880:Piperidines; D011957:Receptors, Opioid; D016627:Oxidopamine; D000094942:Nociceptin Receptor